These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 17409393)

  • 21. T lymphocytes are targets for platelet- and trophoblast-derived microvesicles during pregnancy.
    Pap E; Pállinger E; Falus A; Kiss AA; Kittel A; Kovács P; Buzás EI
    Placenta; 2008 Sep; 29(9):826-32. PubMed ID: 18684502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
    Wang E; Selleri S; Marincola FM
    Clin Cancer Res; 2007 Dec; 13(24):7228-31. PubMed ID: 18094399
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumor-cell-derived microvesicles as carriers of molecular information in cancer.
    Martins VR; Dias MS; Hainaut P
    Curr Opin Oncol; 2013 Jan; 25(1):66-75. PubMed ID: 23165142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function.
    Hedlund M; Stenqvist AC; Nagaeva O; Kjellberg L; Wulff M; Baranov V; Mincheva-Nilsson L
    J Immunol; 2009 Jul; 183(1):340-51. PubMed ID: 19542445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
    Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
    J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More insights into the immunosuppressive potential of tumor exosomes.
    Huber V; Filipazzi P; Iero M; Fais S; Rivoltini L
    J Transl Med; 2008 Oct; 6():63. PubMed ID: 18973649
    [No Abstract]   [Full Text] [Related]  

  • 27. The immune system--is it relevant to cancer development, progression and treatment?
    Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer immunologists and cancer biologists: why we didn't talk then but need to now.
    Prendergast GC; Jaffee EM
    Cancer Res; 2007 Apr; 67(8):3500-4. PubMed ID: 17413003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microparticles, thrombosis and cancer.
    Aharon A; Brenner B
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):61-9. PubMed ID: 19285273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.
    de Souza AP; Bonorino C
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1317-32. PubMed ID: 19761435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The graft-versus-tumor effect and escape of malignancy from immune regulation.
    Malkovska V; Barrett J
    Cancer Chemother Biol Response Modif; 2002; 20():273-89. PubMed ID: 12703209
    [No Abstract]   [Full Text] [Related]  

  • 32. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
    Zamanakou M; Germenis AE; Karanikas V
    Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microvesiculation and disease.
    Inal JM; Fairbrother U; Heugh S
    Biochem Soc Trans; 2013 Feb; 41(1):237-40. PubMed ID: 23356289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microparticles and exosomes in gynecologic neoplasias.
    Nieuwland R; van der Post JA; Lok CA; Kenter G; Sturk A
    Semin Thromb Hemost; 2010 Nov; 36(8):925-9. PubMed ID: 21049392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer.
    Gross S; Walden P
    Immunol Lett; 2008 Feb; 116(1):7-14. PubMed ID: 18164076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of myeloid cells in tumor angiogenesis and growth.
    Shojaei F; Zhong C; Wu X; Yu L; Ferrara N
    Trends Cell Biol; 2008 Aug; 18(8):372-8. PubMed ID: 18614368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells.
    Laudanski K; De A; Miller-Graziano C
    Eur J Immunol; 2007 Oct; 37(10):2812-24. PubMed ID: 17823891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dual effects of interleukin-18 in tumor progression.
    Park S; Cheon S; Cho D
    Cell Mol Immunol; 2007 Oct; 4(5):329-35. PubMed ID: 17976312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour-derived microvesicles modulate biological activity of human monocytes.
    Baj-Krzyworzeka M; Szatanek R; Weglarczyk K; Baran J; Zembala M
    Immunol Lett; 2007 Nov; 113(2):76-82. PubMed ID: 17825925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
    Allavena P; Sica A; Garlanda C; Mantovani A
    Immunol Rev; 2008 Apr; 222():155-61. PubMed ID: 18364000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.